HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 4 (April)

1. Augmentation of HIV-1 subtype C vaccine constructs induced immune response in mice by CpG motif 1826-ODN.
   Viral Immunol, 18(1): 213-23. [Abstract] [Full-text]
2. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages.
   Viral Immunol, 18(1): 190-6. [Abstract] [Full-text]
3. Detection of HIV RNA levels in intraocular and cerebrospinal fluids in patients with AIDS-related cryptococcosis.
   Ophthalmologica, 219(2): 101-6. [Abstract] [Full-text]
4. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
   Br J Clin Pharmacol, 59(4): 398-404. [Abstract] [Full-text]
5. Low plasma selenium concentrations, high plasma human immunodeficiency virus load and high interleukin-6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Malawi.
   Eur J Clin Nutr, 59(4): 526-32. [Abstract] [Full-text]
6. HIV-1 Nef interferes with M-CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities.
   Blood, 105(8): 3230-7. [Abstract] [Full-text]
7. Genotypes of JC virus, DNA of cytomegalovirus, and proviral DNA of human immunodeficiency virus in eyes of acquired immunodeficiency syndrome patients.
   J Neurovirol, 11(1): 58-65. [Abstract] [Full-text]
8. Ocular tuberculosis in acquired immune deficiency syndrome (AIDS).
   Ocul Immunol Inflamm, 13(1): 87-9. [Abstract] [Full-text]
9. Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages.
   Immunology, 114(4): 565-74. [Abstract] [Full-text]
10. Infection with HIV-1 induces a decrease in mtDNA.
    J Infect Dis, 191(9): 1468-71. [Abstract] [Full-text]
11. Viral dynamics of primary HIV-1 infection in Senegal, West Africa.
    J Infect Dis, 191(9): 1460-7. [Abstract] [Full-text]
12. Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children.
    J Infect Dis, 191(9): 1451-9. [Abstract] [Full-text]
13. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies.
    J Infect Dis, 191(9): 1435-41. [Abstract] [Full-text]
14. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.
    J Infect Dis, 191(9): 1427-34. [Abstract] [Full-text]
15. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
    J Infect Dis, 191(9): 1410-8. [Abstract] [Full-text]
16. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
    J Infect Dis, 191(9): 1403-9. [Abstract] [Full-text]
17. Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target.
    Bioorg Med Chem, 13(9): 3209-18. [Abstract] [Full-text]
18. Increasing trend of HIV seropositivity among commercial sex workers attending the Voluntary and Confidential Counseling and Testing Centre in Manipur, India.
    Int J STD AIDS, 16(2): 166-9. [Abstract] [Full-text]
19. Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.
    Clin Exp Immunol, 140(2): 320-4. [Abstract] [Full-text]
20. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.
    HIV Med, 6(2): 140-3. [Abstract] [Full-text]
21. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection?
    HIV Med, 6(2): 135-9. [Abstract] [Full-text]
22. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    HIV Med, 6(2): 129-34. [Abstract] [Full-text]
23. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    HIV Med, 6(2): 122-8. [Abstract] [Full-text]
24. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort.
    HIV Med, 6(2): 114-21. [Abstract] [Full-text]
25. Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
    HIV Med, 6(2): 107-13. [Abstract] [Full-text]
26. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.
    HIV Med, 6(2): 66-78. [Abstract] [Full-text]
27. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London.
    HIV Med, 6(2): 59-65. [Abstract] [Full-text]
28. Acinetobacter baumanii folliculitis in a patient with AIDS.
    Clin Exp Dermatol, 30(3): 256-8. [Abstract] [Full-text]
29. A framework for examining the sustained acceptability of microbicides.
    AIDS Behav, 9(1): 121-31. [Abstract] [Full-text]
30. Demographic characteristics, treatment history, drug risk behaviors, and condom use attitudes for U.S. and Russian injection drug users: the need for targeted sexual risk behavior interventions.
    AIDS Behav, 9(1): 111-20. [Abstract] [Full-text]
31. Risk factors for HIV-AIDS among youth in Cape Town, South Africa.
    AIDS Behav, 9(1): 53-61. [Abstract] [Full-text]
32. Disclosure of HIV status and psychological well-being among Latino gay and bisexual men.
    AIDS Behav, 9(1): 15-26. [Abstract] [Full-text]
33. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis.
    Nat Med, 11(4): S33-44. [Abstract] [Full-text]
34. Trichophyton rubrum isolated from aids and human immunodeficiency virus-infected patients in São Paulo, Brazil: antifungal susceptibility and extracellular enzyme production.
    Chemotherapy, 51(1): 21-6. [Abstract] [Full-text]
35. Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity.
    J Clin Microbiol, 43(4): 1937-9. [Abstract] [Full-text]
36. env Gene typing of human immunodeficiency virus type 1 strains on electronic microarrays.
    J Clin Microbiol, 43(4): 1910-6. [Abstract] [Full-text]
37. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay.
    J Clin Microbiol, 43(4): 1851-7. [Abstract] [Full-text]
38. Pre-organized structure of viral DNA at the binding-processing site of HIV-1 integrase.
    Nucleic Acids Res, 33(6): 1970-81. [Abstract] [Full-text]
39. Aids, race and the limits of science.
    Soc Sci Med, 60(11): 2515-25. [Abstract] [Full-text]
40. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy.
    Gene Ther, 12(8): 694-701. [Abstract] [Full-text]
41. Reference values of CD4 T lymphocytes in human immunodeficiency virus-negative adult Nigerians.
    Clin Diagn Lab Immunol, 12(4): 525-30. [Abstract] [Full-text]
42. Host factors regulating post-integration latency of HIV.
    Trends Microbiol, 13(4): 137-9. [Abstract] [Full-text]
43. Permeability of the blood-brain barrier to HIV-1 Tat.
    Exp Neurol, 193(1): 218-27. [Abstract] [Full-text]
44. Human immunodeficiency virus type 1 transport across the in vitro mouse brain endothelial cell monolayer.
    Exp Neurol, 193(1): 101-9. [Abstract] [Full-text]
45. Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26).
    J Biol Chem, 280(15): 14911-7. [Abstract] [Full-text]
46. Acceptor RNA cleavage profile supports an invasion mechanism for HIV-1 minus strand transfer.
    J Biol Chem, 280(15): 14443-52. [Abstract] [Full-text]
47. Evaluation of HIV-1 kinetic models using quantitative discrimination analysis.
    Bioinformatics, 21(8): 1668-77. [Abstract] [Full-text]
48. Perceptions of local HIV/AIDS prevalence and risks for HIV/AIDS and other sexually transmitted infections: preliminary study of intuitive epidemiology.
    Ann Behav Med, 29(2): 100-5. [Abstract] [Full-text]
49. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial.
    Clin Ther, 26(12): 2045-55. [Abstract] [Full-text]
50. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Curr Biol, 15(7): 661-6. [Abstract] [Full-text]
51. The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils.
    Biochemistry, 44(15): 5853-61. [Abstract] [Full-text]
52. Primordial proteins and HIV.
    J Proteome Res, 4(2): 633-6. [Abstract] [Full-text]
53. Higher frequency of premature stop codon mutations at vpu gene of human immunodeficiency virus type 1 CRF01_AE compared with those of other subtypes.
    Microbes Infect, 7(2): 139-47. [Abstract] [Full-text]
54. HIV epidemic in Central India: trends over 18 years (1986-2003).
    Acta Trop, 93(3): 289-94. [Abstract] [Full-text]
55. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation.
    Microbes Infect, 7(2): 302-9. [Abstract] [Full-text]
56. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    J Virol, 79(9): 5870-4. [Abstract] [Full-text]
57. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa.
    J Virol, 79(9): 5762-73. [Abstract] [Full-text]
58. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
    J Virol, 79(9): 5705-12. [Abstract] [Full-text]
59. Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
    J Virol, 79(9): 5695-704. [Abstract] [Full-text]
60. Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP.
    J Virol, 79(9): 5625-31. [Abstract] [Full-text]
61. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
    J Virol, 79(9): 5616-24. [Abstract] [Full-text]
62. ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity.
    J Virol, 79(9): 5557-67. [Abstract] [Full-text]
63. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
    J Virol, 79(9): 5537-47. [Abstract] [Full-text]
64. Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30.
    J Virol, 79(9): 5529-36. [Abstract] [Full-text]
65. Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanism.
    J Virol, 79(9): 5489-98. [Abstract] [Full-text]
66. Few mutations in the 5' leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses.
    J Virol, 79(9): 5421-7. [Abstract] [Full-text]
67. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.
    J Virol, 79(9): 5386-99. [Abstract] [Full-text]
68. Capacity building for the clinical investigation of AIDS malignancy in East Africa.
    Cancer Detect Prev, 29(2): 133-45. [Abstract] [Full-text]
69. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
    Mol Immunol, 42(9): 1099-109. [Abstract] [Full-text]
70. Sociodemographic factors associated with participation by HIV-1-positive pregnant women in an intervention to prevent mother-to-child transmission of HIV in Cote d'Ivoire.
    Int J STD AIDS, 16(3): 237-42. [Abstract] [Full-text]
71. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    J Med Chem, 48(8): 3036-44. [Abstract] [Full-text]
72. Phenotypic analysis of human immunodeficiency virus type 1 Rev trimerization-interface mutants in human cells.
    J Gen Virol, 86: 1509-13. [Abstract] [Full-text]
73. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
    J Gen Virol, 86: 1499-507. [Abstract] [Full-text]
74. Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach.
    Cancer Res, 65(8): 3347-55. [Abstract] [Full-text]
75. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors.
    Mol Pharmacol, 67(5): 1574-80. [Abstract] [Full-text]
76. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
    Mol Pharmacol, 67(5): 1556-65. [Abstract] [Full-text]
77. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
    J Infect Dis, 191(10): 1680-5. [Abstract] [Full-text]
78. DC-SIGN-mediated transfer of HIV-1 is compromised by the ability of Leishmania infantum to exploit DC-SIGN as a ligand.
    J Infect Dis, 191(10): 1665-9. [Abstract] [Full-text]
79. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.
    Vaccine, 23(26): 3453-68. [Abstract] [Full-text]
80. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.
    Vaccine, 23(26): 3446-52. [Abstract] [Full-text]
81. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Vaccine, 23(26): 3434-45. [Abstract] [Full-text]
82. X-ray structure of RLI, an essential twin cassette ABC ATPase involved in ribosome biogenesis and HIV capsid assembly.
    Structure (Camb), 13(4): 649-59. [Abstract] [Full-text]
83. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.
    J Natl Cancer Inst, 97(8): 577-86. [Abstract] [Full-text]
84. Envelope glycoproteins are dispensable for insertion of host HLA-DR molecules within nascent human immunodeficiency virus type 1 particles.
    Virology, 335(2): 286-90. [Abstract] [Full-text]
85. Opposing effects of the M368A point mutation and deletion of the SP1 region on membrane binding of human immunodeficiency virus type 1 Gag.
    Virology, 335(2): 232-41. [Abstract] [Full-text]
86. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines.
    Virology, 335(2): 177-84. [Abstract] [Full-text]
87. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS.
    J Clin Invest, 115(4): 1082-91. [Abstract] [Full-text]
88. Human T-cell lymphotropic virus antibody prevalence in HIV-1-infected individuals attending a sexual health clinic in South-East London.
    J Med Virol, 76(2): 143-5. [Abstract] [Full-text]
89. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    J Med Virol, 76(2): 146-52. [Abstract] [Full-text]
90. A multicenter evaluation of the PanLeucogating method and the use of generic monoclonal antibody reagents for CD4 enumeration in HIV-infected patients in Thailand.
    Cytometry B Clin Cytom, 65(1): 29-36. [Abstract] [Full-text]
91. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection.
    J Infect, 50(4): 331-7. [Abstract] [Full-text]
92. HIV infection among female drug users in Northern Thailand.
    Drug Alcohol Depend, 78(2): 141-5. [Abstract] [Full-text]
93. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men.
    Drug Alcohol Depend, 78(2): 125-34. [Abstract] [Full-text]
94. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells.
    Nucleic Acids Res, 33(7): 2318-31. [Abstract] [Full-text]
95. Linear indices of the 'macromolecular graph's nucleotides adjacency matrix' as a promising approach for bioinformatics studies. Part 1: prediction of paromomycin's affinity constant with HIV-1 psi-RNA packaging region.
    Bioorg Med Chem, 13(10): 3397-404. [Abstract] [Full-text]
96. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    FEBS Lett, 579(11): 2294-300. [Abstract] [Full-text]
97. Novel single-round PCR and cloning of full-length envelope genes of HIV-1 may yield new insight into biomolecular antibacterial drug development.
    J Virol Methods, 126(1): 111-8. [Abstract] [Full-text]
98. A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription.
    J Biol Chem, 280(17): 17488-96. [Abstract] [Full-text]
99. Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication.
    Mol Ther, 11(5): 677-86. [Abstract] [Full-text]
100. Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete.
     Arch Biochem Biophys, 437(2): 233-40. [Abstract] [Full-text]
101. Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.
     Antimicrob Agents Chemother, 49(5): 2035-43. [Abstract] [Full-text]
102. Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.
     Antimicrob Agents Chemother, 49(5): 1994-2001. [Abstract] [Full-text]
103. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
     Antimicrob Agents Chemother, 49(5): 1907-14. [Abstract] [Full-text]
104. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
     Antimicrob Agents Chemother, 49(5): 1830-6. [Abstract] [Full-text]
105. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.
     Antimicrob Agents Chemother, 49(5): 1761-9. [Abstract] [Full-text]
106. Clinically relevant genotype interpretation of resistance to didanosine.
     Antimicrob Agents Chemother, 49(5): 1739-44. [Abstract] [Full-text]
107. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
     Antimicrob Agents Chemother, 49(5): 1720-6. [Abstract] [Full-text]
108. "I have an evil child at my house": stigma and HIV/AIDS management in a South African community.
     Am J Public Health, 95(5): 808-15. [Abstract] [Full-text]
109. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
     JAMA, 293(16): 2003-11. [Abstract] [Full-text]
110. The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4.
     Curr Biol, 15(8): 714-23. [Abstract] [Full-text]
111. Structural determinants of HIV-1 nucleocapsid protein for cTAR DNA binding and destabilization, and correlation with inhibition of self-primed DNA synthesis.
     J Mol Biol, 348(5): 1113-26. [Abstract] [Full-text]
112. Specific interactions between HIV-1 nucleocapsid protein and the TAR element.
     J Mol Biol, 348(5): 1059-77. [Abstract] [Full-text]
113. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
     Scand J Immunol, 61(4): 347-56. [Abstract] [Full-text]
114. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites.
     Proc Natl Acad Sci U S A, 102(17): 6103-7. [Abstract] [Full-text]
115. Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants.
     Biophys J, 88(5): 3133-46. [Abstract] [Full-text]
116. Implications of increased haemoglobin A2 values in HIV positive women in the antenatal clinic.
     J Clin Pathol, 58(5): 556-8. [Abstract] [Full-text]
117. Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men.
     J Virol, 79(10): 6551-3. [Abstract] [Full-text]
118. Structural elements of the tRNA TPsiC loop critical for nucleocytoplasmic transport are important for human immunodeficiency virus type 1 primer selection.
     J Virol, 79(10): 6532-9. [Abstract] [Full-text]
119. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
     J Virol, 79(10): 6528-31. [Abstract] [Full-text]
120. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.
     J Virol, 79(10): 6523-7. [Abstract] [Full-text]
121. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
     J Virol, 79(10): 6432-40. [Abstract] [Full-text]
122. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
     J Virol, 79(10): 6377-91. [Abstract] [Full-text]
123. Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.
     J Virol, 79(10): 6299-311. [Abstract] [Full-text]
124. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
     J Virol, 79(10): 6122-33. [Abstract] [Full-text]
125. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
     J Virol, 79(10): 6089-101. [Abstract] [Full-text]
126. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
     J Virol, 79(10): 6068-77. [Abstract] [Full-text]
127. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
     J Virol, 79(10): 5996-6004. [Abstract] [Full-text]
128. Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter.
     J Virol, 79(10): 5952-62. [Abstract] [Full-text]
129. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
     J Virol, 79(10): 5907-13. [Abstract] [Full-text]
130. The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy.
     J Health Psychol, 10(3): 345-58. [Abstract] [Full-text]
131. Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons.
     Brain Res Mol Brain Res, 135(1): 48-57. [Abstract] [Full-text]
132. Anti-HIV protease activity from rosa family plant extracts and rosamultin from Rosa rugosa.
     J Med Food, 8(1): 107-9. [Abstract] [Full-text]
133. Glycyrrhizin inhibits R5 HIV replication in peripheral blood monocytes treated with 1-methyladenosine.
     Pathobiology, 72(3): 117-23. [Abstract] [Full-text]
134. Mitochondria are sensors for HIV drugs.
     Trends Pharmacol Sci, 26(5): 258-64. [Abstract] [Full-text]
135. Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate.
     J Med Primatol, 34(2): 101-7. [Abstract] [Full-text]
136. Nef induces apoptosis by activating JNK signaling pathway and inhibits NF-kappaB-dependent immune responses in Drosophila.
     J Cell Sci, 118: 1851-9. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.